Last reviewed · How we verify
Anti-Infective Drugs
Wei Zhao's Anti-Infective Drugs are currently marketed but lack detailed information on their mechanism, primary indication, and revenue, making it challenging to assess their precise market position. The key strength lies in the patent protection, which extends until 2028, providing a period of exclusivity. The primary risk is the limited visibility into clinical trial results and competitive landscape, which could impact future market dynamics.
At a glance
| Generic name | Anti-Infective Drugs |
|---|---|
| Also known as | meropenem, linezolid |
| Sponsor | Wei Zhao |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults (PHASE1)
- A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease (PHASE3)
- MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia (PHASE1)
- Antibiotics vs Surgery in Acute Appendicitis (NA)
- CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease (EARLY_PHASE1)
- Antibiotic Use & Open Fracture of the Lower Extremity (PHASE3)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-Infective Drugs CI brief — competitive landscape report
- Anti-Infective Drugs updates RSS · CI watch RSS
- Wei Zhao portfolio CI